Cargando…

Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors

PURPOSE: Existing fear of cancer recurrence (FCR) screening measures is being shortened to facilitate clinical use. This study aimed to evaluate the validity and screening capacity of a single-item FCR screening measure (FCR-1r) in long-term colorectal cancer (CRC) survivors with no recurrence and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyhne, Johanne Dam, Smith, Allan “Ben”, Timm, Signe, Simard, Sébastien, Jensen, Lars Henrik, Frostholm, Lisbeth, Fink, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638160/
https://www.ncbi.nlm.nih.gov/pubmed/37950072
http://dx.doi.org/10.1007/s00520-023-08159-7
_version_ 1785146562351988736
author Lyhne, Johanne Dam
Smith, Allan “Ben”
Timm, Signe
Simard, Sébastien
Jensen, Lars Henrik
Frostholm, Lisbeth
Fink, Per
author_facet Lyhne, Johanne Dam
Smith, Allan “Ben”
Timm, Signe
Simard, Sébastien
Jensen, Lars Henrik
Frostholm, Lisbeth
Fink, Per
author_sort Lyhne, Johanne Dam
collection PubMed
description PURPOSE: Existing fear of cancer recurrence (FCR) screening measures is being shortened to facilitate clinical use. This study aimed to evaluate the validity and screening capacity of a single-item FCR screening measure (FCR-1r) in long-term colorectal cancer (CRC) survivors with no recurrence and assess whether it performs as well in older as in younger survivors. METHODS: All Danish CRC survivors above 18, diagnosed and treated with curative intent between 2014 and 2018, were located through a national patient registry. A questionnaire including the FCR-1r, which measures FCR on a 0–10 visual analog scale, alongside the validated Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) as a reference standard was distributed between November 2021 and May 2023. Screening capacity and cut-offs were evaluated with a receiver-operating characteristic analysis (ROC) in older (≥ 65 years) compared to younger (< 65 years) CRC survivors. Hypotheses regarding associations with other psychological variables were tested as indicators of convergent and divergent validity. RESULTS: Of the CRC survivors, 2,128/4,483 (47.5%) responded; 1,654 (36.9%) questionnaires were eligible for analyses (median age 76 (range 38–98), 47% female). Of the responders, 85.2% were aged ≥ 65. Ninety-two participants (5.6%) reported FCRI-SF scores ≥ 22 indicating clinically significant FCR. A FCR-1r cut-off ≥ 5/10 had 93.5% sensitivity and 80.4% specificity for detecting clinically significant FCR (AUC = 0.93, 95% CI 0.91–0.94) in the overall sample. The discrimination ability was significantly better in older (AUC = 0.93, 95% CI 0.91–0.95) compared to younger (0.87, 95% (0.82–0.92), p = 0.04) CRC survivors. The FCR-1r demonstrated concurrent validity against the FCRI-SF (r = 0.71, p < 0.0001) and convergent validity against the short-versions of the Symptom Checklist-90-R subscales for anxiety (r = 0.38, p < 0.0001), depression (r = 0.27, p < 0.0001), and emotional distress (r = 0.37, p < 0.0001). The FCR-1r correlated weakly with employment status (r =  − 0.09, p < 0.0001) and not with marital status (r = 0.01, p = 0.66) indicating divergent validity. CONCLUSIONS: The FCR-1r is a valid tool for FCR screening in CRC survivors with excellent ability to discriminate between clinical and non-clinical FCR, particularly in older CRC survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-08159-7.
format Online
Article
Text
id pubmed-10638160
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106381602023-11-14 Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors Lyhne, Johanne Dam Smith, Allan “Ben” Timm, Signe Simard, Sébastien Jensen, Lars Henrik Frostholm, Lisbeth Fink, Per Support Care Cancer Research PURPOSE: Existing fear of cancer recurrence (FCR) screening measures is being shortened to facilitate clinical use. This study aimed to evaluate the validity and screening capacity of a single-item FCR screening measure (FCR-1r) in long-term colorectal cancer (CRC) survivors with no recurrence and assess whether it performs as well in older as in younger survivors. METHODS: All Danish CRC survivors above 18, diagnosed and treated with curative intent between 2014 and 2018, were located through a national patient registry. A questionnaire including the FCR-1r, which measures FCR on a 0–10 visual analog scale, alongside the validated Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) as a reference standard was distributed between November 2021 and May 2023. Screening capacity and cut-offs were evaluated with a receiver-operating characteristic analysis (ROC) in older (≥ 65 years) compared to younger (< 65 years) CRC survivors. Hypotheses regarding associations with other psychological variables were tested as indicators of convergent and divergent validity. RESULTS: Of the CRC survivors, 2,128/4,483 (47.5%) responded; 1,654 (36.9%) questionnaires were eligible for analyses (median age 76 (range 38–98), 47% female). Of the responders, 85.2% were aged ≥ 65. Ninety-two participants (5.6%) reported FCRI-SF scores ≥ 22 indicating clinically significant FCR. A FCR-1r cut-off ≥ 5/10 had 93.5% sensitivity and 80.4% specificity for detecting clinically significant FCR (AUC = 0.93, 95% CI 0.91–0.94) in the overall sample. The discrimination ability was significantly better in older (AUC = 0.93, 95% CI 0.91–0.95) compared to younger (0.87, 95% (0.82–0.92), p = 0.04) CRC survivors. The FCR-1r demonstrated concurrent validity against the FCRI-SF (r = 0.71, p < 0.0001) and convergent validity against the short-versions of the Symptom Checklist-90-R subscales for anxiety (r = 0.38, p < 0.0001), depression (r = 0.27, p < 0.0001), and emotional distress (r = 0.37, p < 0.0001). The FCR-1r correlated weakly with employment status (r =  − 0.09, p < 0.0001) and not with marital status (r = 0.01, p = 0.66) indicating divergent validity. CONCLUSIONS: The FCR-1r is a valid tool for FCR screening in CRC survivors with excellent ability to discriminate between clinical and non-clinical FCR, particularly in older CRC survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-08159-7. Springer Berlin Heidelberg 2023-11-11 2023 /pmc/articles/PMC10638160/ /pubmed/37950072 http://dx.doi.org/10.1007/s00520-023-08159-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Lyhne, Johanne Dam
Smith, Allan “Ben”
Timm, Signe
Simard, Sébastien
Jensen, Lars Henrik
Frostholm, Lisbeth
Fink, Per
Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title_full Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title_fullStr Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title_full_unstemmed Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title_short Validity and screening capacity of the FCR-1r for fear of cancer recurrence in long-term colorectal cancer survivors
title_sort validity and screening capacity of the fcr-1r for fear of cancer recurrence in long-term colorectal cancer survivors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638160/
https://www.ncbi.nlm.nih.gov/pubmed/37950072
http://dx.doi.org/10.1007/s00520-023-08159-7
work_keys_str_mv AT lyhnejohannedam validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT smithallanben validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT timmsigne validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT simardsebastien validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT jensenlarshenrik validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT frostholmlisbeth validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors
AT finkper validityandscreeningcapacityofthefcr1rforfearofcancerrecurrenceinlongtermcolorectalcancersurvivors